6Annemans L, Demarteau N, Hu S, et al. An Asian regional analysis of cost--effectiveness ofearly irbesartan treatment versus conven- tional antihypertensive, late amLodipine, and lateirbesartan treat- ments in patients with type 2 diabetes, hypertension[J], and ne- phropathy. ValueHealth, 2008,3 (11) : 354-364.
7Palmer A J, Valentine WJ, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA[J]. Nephrol Dial Transplant, 2008,4 (23) :1216-1223.
8Balakumar P, Arora MK,Reddy J, et al. Pathophysiology of diabet- ic nephropathy: involvement of multifaeeted signalling mechanism[J]. Cardiovasc Pharmaeol, 2009,2 (54) : 129- 138.
9Martinez Castelao A. Advances in diabetes mellitus, diabetic ne- phropathy, metabolicsyndrome and cardio -- vascular -- renal risk[J]. Nefrologia, 2008,28 Suppl 5 : 79-84.
10American diabetes association. Peripheral arterial disease in people with diabetes[J]. Diabetes Care, 2003, 26 (12): 3333- 3341.
